Study of the Long-Term Effect of Frequent Anti-VEGF Dosing on Retinal Function in Patients With Neovascular AMD

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00533689

Enrollment

2008

Registered

2007-09-21

Start date

2008-01-31

Completion date

2010-01-31

Last updated

2007-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Electrophysiology

Brief summary

THis study aims to determine whether frequent dosing of intravitreal injections of Ranibizumab (Lucentis) or Bevacizumab (Avastin), which act as VEGF inhibitors, has a deleterious effect on the retina, studied by electrophysiologic testing. This prospective, non-randomized clinical study will include patients assigned to intravitreal injection of Ranibizumab or Bevacizumab due to neovascular AMD. The patients will undergo repeat ophthalmic evaluation and intravitreal injections every 4-6 weeks, as long as will be deemed necessary. Periodic electrophysiologic evaluation including Electroretinogram (ERG), electro-oculogram (EOG) and Visual Evoked Potentials (VEP) tests will be performed every 3 months.

Interventions

PROCEDUREElectroretinography (ERG), Visual Evoked Potentials (VEP)

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to 90 Years

Inclusion criteria

* Diagnosis of CNV secondary to AMD * No other ocular disease * No history of kerato-refractive surgery * No epilepsy * Ability to perform electrophysiologic study

Exclusion criteria

* Pregnancy * Minority * Epilepsy * History of kerato-refractive surgery

Countries

Israel

Contacts

Primary ContactMichaella Goldstein, MD

michgold@netvision.net.il+972-3-6925773

Backup ContactShiri Soudry, MD

shirizayit@gmail.com+972-3-6925773

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026